Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents

Author： Aragon-Ching Jeanny   Ning Yang-Min   Chen Clara   Latham Lea   Guadagnini Jean-Pierre   Gulley James   Arlen Philip   Wright John   Parnes Howard   Figg William   Dahut William  

Publisher： Informa Healthcare

ISSN： 0735-7907

Source： Cancer Investigation, Vol.27, Iss.2, 2009-02, pp. : 221-226

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution

By La Verde Nicla  

Supportive Care in Cancer, Vol. 16, Iss. 11, 2008-11 ,pp. : 1311-1315

Springer Publishing Company

Access to resources Recommend Favorite

The Phenomenon of Osteonecrosis of the Jaw in Patients with Metastatic Breast Cancer

By Poznak Catherine  

Cancer Investigation, Vol. 24, Iss. 1, 2006-03 ,pp. : 110-112

Informa Healthcare

Access to resources Recommend Favorite

Osteonecrosis of the jaw in prostate cancer patients with bone metastases treated with zoledronate: A retrospective analysis

By Ortega Cinzia   Montemurro Filippo   Faggiuolo Roberto   Vormola Roberto   Nanni Daniela   Goia Franco   Gilardino Marco Ottavio   Aglietta Massimo  

Acta Oncologica, Vol. 46, Iss. 5, 2007-01 ,pp. : 664-668

Informa Healthcare

Access to resources Recommend Favorite

Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy

By Sternberg C. N.   Molina A.   North S.   Mainwaring P.   Fizazi K.   Hao Y.   Rothman M.   Gagnon D. D.   Kheoh T.   Haqq C. M.   Cleeland C.   de Bono J. S.   Scher H. I.  

Annals of Oncology, Vol. 24, Iss. 4, 2013-04 ,pp. : 1017-1025

Oxford University Press

Access to resources Recommend Favorite

Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer

By Lucarelli Giuseppe   Ditonno Pasquale   Bettocchi Carlo   Spilotros Marco   Rutigliano Monica   Vavallo Antonio   Galleggiante Vanessa   Fanelli Margherita   Larocca Angela Maria Vittoria   Germinario Cinzia Annatea   Maiorano Eugenio   Selvaggi Francesco Paolo   Battaglia Michele  

Future Oncology, Vol. 9, Iss. 6, 2013-06 ,pp. : 899-907

Future Medicine

Access to resources Recommend Favorite